Earnings Insights · Quantum Computing (QUBT) · Q3 FY2026

Quantum Computing (QUBT) Q3 FY2026: Quantum Computing Inc. Q3 2026 Earnings: Acquisitions Drive Revenue Surge, but Margins Remain Thin

By AlgovestIQ ResearchPublished

Share

Read Quantum Computing’s results announcement (Form 8-K, filed Nov 9, 2026)

Key earnings findings

Quantum Computing (QUBT) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Quantum Computing reported Q3 FY2026 revenue of $9.5M against the $7.6M analyst estimate, a 24.8% beat, and EPS of -$0.07 against the -$0.04 analyst estimate.
  2. QUBT closed at $6.30 on Nov 10, 2026, down 8.2% from $6.86 on Nov 9, 2026, the last close before the results were released.
  3. Quantum Computing Inc. reported third-quarter revenue of $9.5M, up from $384K a year earlier and exceeding the $9.2M generated during the first half of 2026.

Sources: Quantum Computing results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Quantum Computing beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$9.5M
$7.6M
+24.8%
EPS
-$0.07
-$0.04
—
  • Revenue surprise across the last 8 reported quarters has ranged from -69.0% to 229.1%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Quantum Computing Inc. reported third-quarter revenue of $9.5M, up from $384K a year earlier and exceeding the $9.2M generated during the first half of 2026. The company reported a GAAP net loss of $15.1M, or $0.07 per basic share, as spending on personnel, research, sales and acquisition integration rose sharply.

The quarter shows that QCi’s acquired photonics, quantum communications and advanced-packaging businesses are creating a materially larger commercial revenue base. However, the 4.5% gross margin and $28.6M operating loss show that the central challenge has shifted from assembling capabilities to improving manufacturing utilization, converting backlog and proving that the expanded platform can generate sustainable returns.

As Reported on the Call

MetricReportedChange
Revenue$9.5MUp from $384K in Q3 2025
Gross profit$428KUp from $126K
Gross margin4.5%—
Operating expenses$29.0MUp from $10.5M
Operating loss$28.6MCompared with a $10.4M loss
Interest and other income$13.0MUp from $3.5M
GAAP net income (loss)$(15.1M)Compared with $2.4M income
GAAP EPS$(0.07)Compared with $0.01 income per share
Cash, cash equivalents and investmentsApproximately $1.3BConsistent with Q2
Contract backlog$39.1M—
Working capital$916.9M—

The Bigger Story

QCi’s third-quarter revenue growth primarily reflects the acquisitions of Luminar Semiconductors, NuCrypt and NHanced completed in the first half of 2026. Those businesses added established sales of photonic components, quantum communications products and advanced packaging services, largely to aerospace, government and industrial customers.

That changes the company’s near-term revenue profile. QCi is no longer relying solely on early-stage quantum-computing product commercialization; it now has manufacturing operations and customer relationships in more established photonics markets. The strategic case is that these operations can both generate current commercial revenue and support development of QCi’s proprietary quantum products.

The tradeoff is that the acquired operations have not yet produced attractive consolidated margins. Cost of revenue was $9.1M against $9.5M of revenue, leaving only $428K of gross profit. Investors therefore need to distinguish between the important step-up in revenue scale and evidence of a proven, profitable operating model, which has yet to emerge.

Revenue and Operating Performance

Revenue reached $9.5M in the third quarter, compared with $384K in the prior-year period. Management said sales of photonic products and services for aerospace, government and industrial applications drove the increase, with the acquired businesses providing the principal commercial contribution.

The quarter’s revenue also exceeded the $9.2M recorded in the first six months of 2026. That reflects the timing of acquired-business contributions as well as a substantially broader operating footprint following the acquisitions.

Contract backlog stood at $39.1M at September 30. Management said backlog generally converts over roughly 12 to 18 months, although timing can vary because the company produces technologically complex products in relatively small volumes. Management also characterized the backlog as predominantly aerospace and government-related, with roughly 70% tied to those markets, much of it through subcontract work.

This mix provides a visible base of contracted work, but it also leaves QCi exposed to the timing, funding and completion of government and aerospace programs. Management expects the customer mix to become more balanced over time as commercial adoption expands, but government-related work remains the primary near-term revenue source.

On the quantum-computing side, QCi introduced its Dirac-3 optimization system, which management said is designed to address problems involving up to 9,980 variables. Management expects the first customer shipment in the fourth quarter and said existing Dirac customers could be candidates to upgrade. These developments are strategically relevant, but they should not yet be confused with a material source of current revenue.

Profitability and Margins

Gross margin was 4.5% in the third quarter, reflecting $428K of gross profit on $9.5M of revenue. The low margin is the clearest constraint in the quarter: commercial revenue expanded rapidly, but nearly all of that revenue was consumed by product and service delivery costs.

Management attributed the margin outlook to manufacturing utilization and operating efficiency. Its thesis is that higher production volumes, better integration across facilities and greater use of the company’s manufacturing assets can improve gross margin over time. That outcome remains an execution objective rather than a reported result.

Operating expenses increased to $29.0M from $10.5M a year earlier. Research and development expense rose to $8.3M from $4.5M, sales and marketing expense increased to $5.3M from $787K, and general and administrative expense rose to $15.4M from $5.2M. The company said the increase reflected higher personnel costs, expanded R&D and commercial activity, and approximately $1.0M of acquisition-related expenses.

The result was a $28.6M operating loss, compared with a $10.4M operating loss in the prior-year period. Interest and other income of $13.0M, generated primarily from QCi’s sizable investment balances, partly offset the operating loss. The company ultimately reported a $15.1M net loss, compared with net income of $2.4M in the prior-year quarter.

The comparison with last year’s net income is also affected by a smaller gain from the change in fair value of a derivative liability. That gain was $458K in the third quarter, versus $9.2M a year earlier. As a result, the prior-year net income was not a useful indicator of recurring operating profitability.

Management said the third-quarter operating-expense level is a reasonable near-term run rate, excluding roughly $1M of trailing acquisition-related costs. Headcount continued to increase, however, reaching more than 330 employees from roughly 310 to 320 at the end of the second quarter. That suggests operating expenses could rise gradually as QCi expands its workforce and manufacturing activity.

Demand, Customers and Pricing

Management described demand as strongest in aerospace, government and industrial photonics markets, while quantum opportunities remain earlier-stage and application-specific. The company is pursuing commercial applications for its optimization systems, including computing-resource efficiency in data centers, pharmaceutical and biotechnology research, and defense-related work.

During the quarter, QCi entered a commercial agreement with INmune Bio to explore the use of Dirac quantum optimization technology, AI and conventional analytics in clinical and biomedical data. The arrangement is QCi’s first commercial customer engagement in pharmaceutical and biotechnology. It may broaden the company’s application set, but management described the work as exploratory rather than as an established recurring revenue stream.

QCi also entered a framework agreement with Hamad Bin Khalifa University in Qatar covering quantum education, research and co-marketing initiatives, including cloud access to its Dirac-3 system. The agreement supports technology awareness and research use, although it should not be viewed as a material commercial order.

Management said the bulk of current revenue and backlog is domestic. International sales remain a longer-term opportunity, but management noted that advanced technologies may face export-control or other regulatory constraints that could complicate expansion outside the U.S.

What is QCi’s outlook for Q4 2026 and beyond?

QCi did not issue formal financial guidance for revenue, EPS, margins or cash flow.

Management expects the first Dirac-3 customer shipment during the fourth quarter and said it is working to upgrade existing systems and expand cloud access. It also expects the acquired photonics and manufacturing operations to support a stronger backlog and broader commercial customer base over the next 12 to 18 months.

The company’s operational priorities are to grow commercial revenue, scale manufacturing and advance its quantum portfolio. Management said it has completed the objectives in its 2024-to-2026 portfolio roadmap and is moving toward further product-line and manufacturing scale.

A key planned milestone is the development of heterogeneously integrated photonic circuits combining capabilities across QCi’s acquired operations. Management said it hopes to demonstrate these circuits within 12 to 18 months, potentially sooner. Such integration could be important to reducing the size and improving the manufacturability of future quantum systems, but it remains in development.

Balance Sheet, Cash Flow and Capital

QCi ended the quarter with approximately $1.3B in cash, cash equivalents, investments and accrued interest. This included $174.3M of cash and cash equivalents, $727.3M of short-term investments and $396.2M of long-term investments.

The company had $916.9M in working capital and total liabilities of $47.7M at quarter-end. Management said its liquidity should fund operations for at least the next 12 months, providing flexibility to invest in manufacturing and technology development without an immediate need to raise capital.

That capital base is a major strategic advantage for a company still operating at a substantial loss and building capital-intensive manufacturing capabilities. Management said it has earmarked several hundred million dollars for capital investment and expects approximately $70M to $80M of spending related to the NHanced-based “Fab 2” expansion. Much of that spending is expected between now and the end of the second quarter of 2027.

Management said it has begun ordering equipment and will continue evaluating acquisition opportunities. Any further acquisitions, however, would need to be assessed against the company’s ability to integrate recent deals, improve returns on existing assets and preserve sufficient working capital.

What Investors Should Watch

1. Gross-margin improvement

The 4.5% gross margin is the most important financial limitation in the current model. Investors should watch whether higher utilization and facility integration produce measurable margin expansion as photonics revenue grows.

2. Backlog conversion and customer diversification

The $39.1M backlog provides some near-term revenue visibility, but conversion timing can be uneven. Growth in commercial orders outside aerospace and government markets would help validate management’s goal of reducing reliance on government-related programs.

3. Dirac-3 customer adoption

The expected first Dirac-3 shipment in the fourth quarter is an important product milestone. The more meaningful evidence will be follow-on orders, upgrades from existing users and commercial use cases that translate into recurring revenue.

4. Capital deployment and acquisition integration

QCi has substantial liquidity, but it is also planning $70M to $80M of manufacturing investment and remains open to additional acquisitions. Investors should monitor whether those investments improve manufacturing capacity, product integration and margins rather than simply expanding the cost base.

5. Operating-expense discipline

Management views third-quarter operating expense as a reasonable near-term baseline, excluding acquisition costs. The company will need revenue and gross profit to scale more quickly than payroll, R&D and facility spending if it is to narrow operating losses.

AlgovestIQ Takeaway

QCi’s third quarter marked a clear change in scale. Revenue of $9.5M was far above the company’s historical levels and was supported by acquired businesses with existing products, manufacturing assets and customer relationships. The $39.1M backlog and $1.3B liquidity position give QCi more commercial and financial substance than a pure early-stage quantum technology developer.

Still, the revenue increase does not yet establish an attractive earnings model. A 4.5% gross margin and $28.6M operating loss show that the company remains in an expensive integration and expansion phase. Interest income meaningfully reduced the net loss, but it does not solve the underlying issue of low gross profitability.

The central investment question is whether QCi can turn its acquired photonics and advanced-packaging operations into a higher-utilization manufacturing platform that supports both current commercial sales and future quantum products. Management’s planned Fab 2 investment, cross-site integration work and Dirac-3 launch are all designed to address that question.

Evidence that would strengthen the thesis includes backlog growth, improved gross margin, successful Dirac-3 deployments and a broader commercial customer base. Conversely, weak backlog conversion, persistently low manufacturing margins, rising operating costs or capital spending that does not produce clear commercial progress would weaken the case that QCi’s expanded platform can become a sustainable business.

How did QUBT stock react?

QUBT closed at $6.30 on Nov 10, 2026, down 8.2% from $6.86 on Nov 9, 2026, the last close before the results were released.

SessionCloseChange
Nov 9, 2026 (before release)$6.86—
Nov 10, 2026$6.30-8.2%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Quantum Computing Q3 FY2026 earnings call transcript, as of Nov 9, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Quantum Computing Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 9, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 9, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Quantum Computing's earnings release and call transcript before publication. Not investment advice.